Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma.
10.3760/cma.j.issn.0253-2727.2019.11.005
- Author:
Xue Lian LIU
1
;
Yan Ping YANG
;
Jing BAI
;
Ting Ting YUE
;
Pei Yu YANG
;
Ye ZHANG
;
Hong Qiong FAN
;
Wei LI
;
Feng Yan JIN
Author Information
1. Department of Hematology, Cancer Center, the First Affiliated Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- Keywords:
Cytogenetic abnormality;
Double hit;
ISS stage;
Multiple myeloma;
Prognosis
- MeSH:
Chromosome Aberrations;
Chromosomes, Human, Pair 1;
Chromosomes, Human, Pair 17;
Humans;
Multiple Myeloma;
Neoplasm Staging;
Prognosis;
Retrospective Studies;
Survival Analysis
- From:
Chinese Journal of Hematology
2019;40(11):912-917
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the prognostic significance of combining ISS-Ⅲ and high risk cytogenetic abnormalities [HRCAs, including 1q gain/amplification and del (17p) ] in patients with newly-diagnosed multiple myeloma (NDMM) . Methods: The clinical characteristics and relevant variables were retrospectively analyzed in a total of 270 NDMM patients diagnosed between November 2009 and May 2018. ISS-Ⅲ stage and HRCAs [detected by FISH, including 1q gain/amplification and del (17p) ] were defined as risk factors (hit) . Based to the number of hit per case, these patients were divided into four groups carrying 0 to 3 risk factors, respectively. Progress-free survival (PFS) and overall survival (OS) were then analyzed using the Kaplan-Meier estimator. Results: Patients who carried single hit (n=120, 44.4%) had shorter median PFS (23.0 vs 28.9 months; P>0.05) and OS (42.3 vs 53.7 months; P>0.05) than those with no risk factors (n=66, 24.4%) . Of note, the outcome of patients who had two or more risk factors (double/triple, n=84, 31.1%) was much worse than those with either no or one risk factor, indicated by significantly reduced median PFS (14.5 months; HR=1.584, 95%CI 1.082-2.319; P=0.003 for double/triple vs single hit) and OS (18.4 months, HR=2.299, 95%CI 1.485-3.560; P<0.001 for double/triple vs single hit) . Strikingly, patients who had three risk factor (triple hit, n=5, 1.9%) displayed the poorest survival with extraordinarily shorter PFS (0.9-15.1 months) and OS (0.9-18.9 months) compared to those carrying two risk factors (double hit) . Analogous results were obtained when different combinations of ISS stages and HRCAs were analyzed. Conclusion: These results suggest a potential but rather important role of combining multiple (e.g. double or triple) adverse factors determined via the routine ISS staging and FISH detection of cytogenetic abnormalities in risk stratification and prognostic prediction, which might be helpful to identify high risk patients more precisely at diagnosis. It also raised a possibility that a small group of ISS-Ⅲ patients carrying both 1q gain/amplification and del (17p) might represent an "extremely-high risk" subset of MM.
